BFC Planning’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
BFC Planning's AXSM Position: Q3 2026 in Review
BFC Planning reduced its Axsome Therapeutics (AXSM) stake by 15% in Q3 2026, selling an estimated $870 and leaving 22 shares worth $4.06K. The position accounts for ﹤0.01% of the portfolio, ranked #2767.
BFC Planning first reported a position in AXSM in Q3 2024 and has held it in 9 quarters since. The position peaked at $6.94K in Q4 2025. 349 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- BFC Planning held 22 shares of Axsome Therapeutics worth $4.06K as of Q3 2026.
- BFC Planning sold 4 Axsome Therapeutics shares in Q3 2026, an estimated $870.
- Axsome Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2767 holding.
- BFC Planning first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Axsome Therapeutics position peaked at $6.94K in Q4 2025.
- 349 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.